New hope for hard-to-treat colon cancer: drug combo tested in clinical trial
NCT ID NCT07261709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares a new drug combination (trifluridine/tipiracil plus fruquintinib) against a standard one (trifluridine/tipiracil plus bevacizumab) in 236 people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the new combo works as well or better at controlling the cancer and improving survival. Participants take oral pills and receive intravenous infusions over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trifluridine/tipiracil plus fruquintinib
What this could lead to
If this works, it could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong
This is an early phase 2 trial with only 236 participants, so results may not apply to everyone. The new combo might not be as effective or safe as the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••